Website

Mapping Global Networks in HIV Vaccine Research

ACO Annual CHVI R&D Alliance Meeting,
Toronto, Ontario, April 30,2015
Theme: HIV Vaccine Networks: Collaborations, Partnerships and Outcomes across Sectors and Borders
Join us at this full-day ancillary event to the CAHR 2015 conference!
Speakers will include Frank Plummer of the Public Health Agency of Canada and the University of Manitoba; Silvija Staprans of the Bill & Melinda Gates Foundation; Amapola Manrique from the Global HIV Vaccine Enterprise; and Galit Alter from Harvard University, among others. Download Preliminary Agenda. Advanced registration is required due to limited capacity and to plan for lunch.
Register online by April 15, 2015. Email us for more information.
Download Poster

Upcoming Webinar

Science Communication: From Page to Stage

Date: Wednesday, March 18, 2015
Time: 1:00 - 2:45 PM EDT (12:00-1:45 PM CDT, 11:00 AM - 12:45 PM MDT and 10:00 - 11:45 AM PDT)
Presenter: Dr. Jennifer Gardy, Senior Scientist, BC Centre for Disease Control; Assistant Professor, School of Population and Public Health, UBC; Associate Member, Microbiology, UBC

News and Features

Product Development Boot Camp

The Global HIV Vaccine Enterprise, in collaboration with SHI Consulting is organizing a two-day Product Development Boot Camp featuring modules that will combine presentations by product development experts, introduction to new tools and resources, and active learning through discussion with peers and experts.

Date: September-October, 2015
Duration: 2 days
Location: East Coast US
Size: 40-50 participants (with some sessions webcast and available for remote viewing)

New Report: HIV Prevention on the Line

AVAC recently published AVAC Report 2014/15: HIV Prevention on the Line – a roadmap and discussion-starter on how to advance comprehensive combination prevention, including delivery of existing tools, demonstration of the potential of emerging strategies and discovery of novel interventions like an effective preventive AIDS vaccine. The full PDF, summary slides, graphics and other resources are available online.

Funding Opportunities

Canadian Institutes of Health Research

→ Catalyst Grant : HIV/AIDS Community-Based Research (2015)
Application Deadline: April 15, 2015
The total amount available for this funding opportunity is $198,000, enough to fund approximately six grants. The maximum amount per grant is $33,000 for up to one year.
LEARN MORE

→ Knowledge Synthesis Grant: Spring 2015 Competition
Application Deadline: May 15, 2015
LEARN MORE

Career Opportunity

Centre for the AIDS Programme of Research in South Africa

CAPRISA has an exciting opportunity available for a suitably qualified and experienced Senior Scientist to join the CAPRISA Vulindlela Clinical Research Team as the Site Director. The appointed candidate will lead, manage and coordinate research, and ensure the successful implementation of clinical trials within Vulindlela and surrounding areas, advance the scientific agenda through new ideas, publications, grant writing, and staff supervision for higher degrees.

Opinion

In Childhood Vaccine Controversy, an Indirect Lesson for HIV/AIDS Advocates

TheBodyPRO.com, Feb. 19, 2015 By Mitchell Warren, AVAC From all the recent attention to parents' rejection of vaccines and a possible resurgence of measles in the U.S., one welcome theme has emerged: Such a controversy could never occur if vaccines weren't so powerfully effective in the first place.

New Research

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

Plos Pathogens, Feb. 27, 2015 DOI: 10.1371/journal.ppat.1004658
Hancock G, Yang H, Yorke E, et al

Authors observed that CD8+ T cells from patients with naturally low plasma viral loads (viremic controllers) were better able to inhibit the replication of diverse HIV strains in vitro than CD8+ T cells from HIV-noncontroller patients. They also found that the potency of the antiviral activity in the latter group was strongly correlated with recognition of selected regions across the viral proteome that are critical to viral fitness. Vaccines that encode full-length viral proteins rarely elicited responses to these vulnerable regions. Taken together, these results provide insight into the characteristics of effective cell-mediated immune responses against HIV and how these may inform the design of better immunogens.

Annual Update

Annual Update PDF

You are receiving this email because you registered to receive news updates from the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office
or you are a member of a CHVI-funded
project team.

Follow Us:

Update Subscription Preferences

Privacy Policy

Unsubscribe

Subscribe

Send to a Friend